Loomis Sayles & Co. L P Sells 202,443 Shares of Astrana Health, Inc. (NASDAQ:ASTH)

Loomis Sayles & Co. L P decreased its holdings in shares of Astrana Health, Inc. (NASDAQ:ASTH) by 38.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 319,666 shares of the company’s stock after selling 202,443 shares during the period. Loomis Sayles & Co. L P’s holdings in Astrana Health were worth $10,079,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in ASTH. Quarry LP acquired a new stake in shares of Astrana Health during the 3rd quarter worth about $77,000. KBC Group NV increased its holdings in shares of Astrana Health by 108.4% during the fourth quarter. KBC Group NV now owns 2,530 shares of the company’s stock worth $80,000 after buying an additional 1,316 shares in the last quarter. US Bancorp DE raised its stake in shares of Astrana Health by 3,880.0% in the fourth quarter. US Bancorp DE now owns 4,776 shares of the company’s stock valued at $151,000 after acquiring an additional 4,656 shares during the last quarter. Paloma Partners Management Co acquired a new position in shares of Astrana Health in the 3rd quarter worth approximately $220,000. Finally, Quantbot Technologies LP bought a new stake in Astrana Health during the 3rd quarter worth approximately $244,000. 52.77% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on ASTH shares. Macquarie upgraded Astrana Health to a “hold” rating in a research report on Monday, December 16th. Stifel Nicolaus reduced their price target on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Truist Financial lowered their price objective on shares of Astrana Health from $50.00 to $46.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th. Robert W. Baird reduced their target price on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. Finally, Bank of America lowered their price target on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $56.17.

Astrana Health Stock Down 2.6 %

Shares of NASDAQ:ASTH opened at $30.54 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of 23.49, a P/E/G ratio of 1.37 and a beta of 1.30. The company has a 50 day moving average of $33.85 and a 200-day moving average of $41.94. Astrana Health, Inc. has a one year low of $23.12 and a one year high of $63.20.

Astrana Health (NASDAQ:ASTH) last issued its earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $665.21 million for the quarter, compared to the consensus estimate of $617.24 million. On average, sell-side analysts forecast that Astrana Health, Inc. will post 1.15 earnings per share for the current year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.